Comparison of Pulmonary Involvement Between Patients Expressing Anti-PL-7 and Anti-Jo-1 Antibodies

详细信息    查看全文

• 作者：Masaomi Tomonaga (1)
  Noriho Sakamoto (1)
  Yuji Ishimatsu (1)
  Tomoyuki Kakugawa (1)
  Tatsuhiko Harada (1)
  Shota Nakashima (1)
  Atsuko Hara (1)
  Shintaro Hara (1)
  Yoshihiro Horai (2)
  Atsushi Kawakami (2)
  Hiroshi Mukae (3)
  Shigeru Kohno (1)
  
  1. Second Department of Internal Medicine ; Nagasaki University School of Medicine ; 1-7-1 Sakamoto ; Nagasaki ; 852-8501 ; Japan
  2. Unit of Translational Medicine ; Department of Immunology and Rheumatology ; Nagasaki University Graduate School of Biomedical Sciences ; Nagasaki ; Japan
  3. Department of Respiratory Medicine ; University of Occupational and Environmental Health ; Kitakyushu ; Japan
  
• 关键词：Antisynthetase syndrome ; Interstitial lung disease ; Dermatomyositis ; Polymyositis
• 刊名：Lung
• 出版年：2015
• 出版时间：February 2015
• 年：2015
• 卷：193
• 期：1
• 页码：79-83
• 全文大小：159 KB
• 参考文献：1. Hervier B, Devilliers H, Stanciu R et al (2012) Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev 12:210鈥?17 CrossRef
  2. Ronnelid J, Barbasso Helmers S, Storfors H et al (2009) Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies. Autoimmun Rev 9:58鈥?1 CrossRef
  3. Hamaguchi Y, Fujimoto M, Matsushita T et al (2013) Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One 8:e60442 CrossRef
  4. Hervier B, Benveniste O (2013) Clinical heterogeneity and outcomes of antisynthetase syndrome. Curr Rheumatol Rep 15:349 CrossRef
  5. Marie I (2012) Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep 14:275鈥?85 CrossRef
  6. Marie I, Josse S, Decaux O et al (2013) Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome. Eur J Intern Med 24:474鈥?79 CrossRef
  7. Tillie-Leblond I, Wislez M, Valeyre D et al (2008) Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax 63:53鈥?9 CrossRef
  8. Ingegnoli F, Lubatti C, Ingegnoli A et al (2012) Interstitial lung disease outcomes by high-resolution computed tomography (HRCT) in anti-Jo1 antibody-positive polymyositis patients: a single centre study and review of the literature. Autoimmun Rev 11:335鈥?40 CrossRef
  9. Marie I, Josse S, Hatron PY et al (2013) Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome. Arthritis Care Res 65:800鈥?08 CrossRef
  10. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403鈥?07 CrossRef
  11. Sontheimer RD (2002) Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46:626鈥?36 CrossRef
  12. Sakamoto N, Mukae H, Fujii T et al (2004) Soluble form of Fas and Fas ligand in serum and bronchoalveolar lavage fluid of individuals infected with human T-lymphotropic virus type 1. Respir Med 98:213鈥?19 CrossRef
  13. Meyer KC, Raghu G, Baughman RP et al (2012) An official american thoracic society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 185:1004鈥?014 CrossRef
  14. American Thoracic Society ERS (2000) Idiopathic pulmonary fibrosis: diagnosis and treatment. international consensus statement. Am J Respir Crit Care Med 161:646鈥?64 CrossRef
  15. Hervier B, Uzunhan Y, Hachulla E et al (2011) Antisynthetase syndrome positive for anti-threonyl-tRNA synthetase (anti-PL7) antibodies. Eur Respir J 37:714鈥?17 CrossRef
  16. Schnabel A, Reuter M, Biederer J et al (2003) Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum 32:273鈥?84 CrossRef
  17. Marie I, Josse S, Decaux O et al (2012) Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev 11:739鈥?45 CrossRef
  18. Aggarwal R, Cassidy E, Fertig N et al (2014) Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 73:227鈥?32
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Pneumology and Respiratory System
  
• 出版者：Springer New York
• ISSN：1432-1750

文摘

Anti-PL-7 is an anti-tRNA synthetase antibody, and interstitial lung disease (ILD) is the most frequent complication of anti-PL-7-associated antisynthetase syndrome. However, the features of ILD have not been fully elucidated. The present study retrospectively compares 7 and 15 patients who were positive for anti-PL-7 and anti-Jo-1 antibodies, respectively. The features of ILD did not significantly differ between the two groups, but the ratio of lymphocytes in bronchoalveolar lavage fluid was higher in the Jo-1 than in the PL-7 group. High-resolution computed tomography revealed nonspecific interstitial pneumonia in all patients in the PL-7 group and organizing pneumonia in four of the 15 patients in the Jo-1 group. These findings suggest that pulmonary complications slightly differ between patients expressing anti-PL-7 and anti-Jo-1 antibodies. Further studies are required to clarify the features of ILD associated with PL-7.